Patents by Inventor Shi Yin FOO

Shi Yin FOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DSG2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19
    Publication number: 20240043495
    Abstract: The disclosure generally relates to compositions and methods of treating COVID-19 by administering compositions disclosed herein. The methods also include the treatment of post-COVID-19 syndrome and cardiomyopathies using compositions described in the present disclosure.
    Type: Application
    Filed: June 13, 2023
    Publication date: February 8, 2024
    Applicant: Arvada Therapeutics, Inc.
    Inventors: Shi Yin Foo, Ryan Edward Tyler
  • USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
    Publication number: 20210317202
    Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 14, 2021
    Inventors: Craig BASSON, Mark C. FISHMAN, Shi Yin FOO, Tom THUREN
  • PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE
    Publication number: 20210177845
    Abstract: The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
    Type: Application
    Filed: February 26, 2021
    Publication date: June 17, 2021
    Inventors: Edward George CALAMAI, Deborah Lynn Leithead DOBBINS, Michael Paul DEHART, James MCARTHUR, Shi Yin FOO
  • USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
    Publication number: 20200148759
    Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.
    Type: Application
    Filed: June 21, 2019
    Publication date: May 14, 2020
    Inventors: Craig Basson, Tom Thuren, Shi Yin Foo, Mark C. Fishman
  • USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
    Publication number: 20180258166
    Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 13, 2018
    Inventors: Craig Basson, Tom Thuren, Shi Yin Foo, Mark C. Fishman
  • Use of IL-1 ? binding antibodies for treating peripheral arterial disease
    Patent number: 10000565
    Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: June 19, 2018
    Assignee: Novartis AG
    Inventors: Craig Basson, Mark Fishman, Tom Thuren, Shi Yin Foo
  • USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
    Publication number: 20160326243
    Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.
    Type: Application
    Filed: November 14, 2013
    Publication date: November 10, 2016
    Applicant: Novartis AG
    Inventors: Craig Basson, Mark Fishman, Tom Thuren, Shi Yin Foo
  • Method of treating contrast-induced nephropathy
    Patent number: 8993631
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventor: Shi Yin Foo
  • METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY
    Publication number: 20140336194
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: NOVARTIS AG
    Inventor: Shi Yin FOO
  • METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY
    Publication number: 20120122844
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventor: Shi Yin FOO